Acanthamoeba species from a post-covid patient with CSF rhinorrhea; a next possible post covid menace? A case report

Archana Keche; Sharmistha Chakravarty; Shagufta Khatoon; Pankaj Kannauje; Ripu Daman Arora

doi:10.1016/j.ijmmb.2022.09.014

Acanthamoeba species from a post-covid patient with CSF rhinorrhea; a next possible post covid menace? A case report

Indian J Med Microbiol. 2023 Mar-Apr:42:100-102. doi: 10.1016/j.ijmmb.2022.09.014. Epub 2022 Oct 14.

Authors

Archana Keche¹, Sharmistha Chakravarty², Shagufta Khatoon³, Pankaj Kannauje⁴, Ripu Daman Arora⁵

Affiliations

¹ Department of Microbiology, AIIMS Raipur, India. Electronic address: [email protected].
² Department of Otolaryngology & Head Neck Surgery, AIIMS Raipur, India. Electronic address: [email protected].
³ Department of Microbiology, AIIMS Raipur, India. Electronic address: [email protected].
⁴ Department of Medicine, AIIMS Raipur, India. Electronic address: [email protected].
⁵ Department of Otolaryngology & Head Neck Surgery, AIIMS Raipur, India. Electronic address: [email protected].

Abstract

A case of Acanthamoeba rhinorrhea in a 32 years female, who was recently recovered from COVID-19 infectionat a tertiary care institute in India. Though, there was no standard treatment protocol for management of amoebic-meningo encephalitis. The patient was managed successfully with combination therapy of amphotericin B and miltefosine. Agents having trophicidal and cysticidal activities are used for treatment of CNS Acanthamoeba infection. COVID 19 infection, steroid therapy anddiabetes mellitus which lead to low immunitywere found to be associated contributing factors.

Keywords: Acanthamoeba; COVID19; Rhinorrhea.

Publication types

Case Reports
Comment

MeSH terms

Acanthamoeba*
Amebiasis* / diagnosis
Amebiasis* / drug therapy
Amphotericin B
COVID-19*
Cerebrospinal Fluid Rhinorrhea*
Female
Humans

Substances

Amphotericin B